Valneva SE (0OB3.L)
EUR 1.82
(2.0%)
EUR 1.82
(2.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -82.08 Million EUR | 8.25% |
| 2022 | -113.44 Million EUR | -84.79% |
| 2021 | -61.39 Million EUR | -11.4% |
| 2020 | -55.11 Million EUR | -3766.67% |
| 2019 | 1.5 Million EUR | -75.99% |
| 2018 | 6.26 Million EUR | 258.35% |
| 2017 | -3.95 Million EUR | 90.71% |
| 2016 | -42.56 Million EUR | -113.54% |
| 2015 | -19.93 Million EUR | 16.3% |
| 2014 | -23.81 Million EUR | -14.2% |
| 2013 | -20.85 Million EUR | -62.52% |
| 2012 | -12.83 Million EUR | -188.32% |
| 2011 | -4.45 Million EUR | 47.12% |
| 2010 | -8.41 Million EUR | -33.71% |
| 2009 | -6.29 Million EUR | -99.59% |
| 2008 | -3.15 Million EUR | 34.09% |
| 2007 | -4.78 Million EUR | -2065.16% |
| 2006 | -221 Thousand EUR | 84.55% |
| 2005 | -1.43 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -25.54 Million EUR | 13.14% |
| 2024 Q2 | -24.98 Million EUR | 15.65% |
| 2023 Q3 | -22.21 Million EUR | -20.78% |
| 2023 Q1 | -16.57 Million EUR | 70.59% |
| 2023 Q4 | -29.4 Million EUR | -32.38% |
| 2023 Q2 | -18.39 Million EUR | -10.97% |
| 2023 FY | -104.08 Million EUR | 8.25% |
| 2022 Q2 | -131.98 Million EUR | -616.47% |
| 2022 FY | -113.44 Million EUR | -84.79% |
| 2022 Q4 | -56.35 Million EUR | -160.39% |
| 2022 Q3 | 93.31 Million EUR | 170.7% |
| 2022 Q1 | -18.42 Million EUR | -110.45% |
| 2021 Q2 | -55.03 Million EUR | -76.74% |
| 2021 Q1 | -31.13 Million EUR | -1085.31% |
| 2021 FY | -61.39 Million EUR | -11.4% |
| 2021 Q3 | -151.43 Million EUR | -175.16% |
| 2021 Q4 | 176.21 Million EUR | 216.37% |
| 2020 Q3 | -30.56 Million EUR | -38.83% |
| 2020 FY | -55.11 Million EUR | -3766.67% |
| 2020 Q2 | -22.01 Million EUR | -25118.18% |
| 2020 Q1 | 88 Thousand EUR | -96.39% |
| 2020 Q4 | -2.62 Million EUR | 91.41% |
| 2019 Q2 | -7.95 Million EUR | -228.14% |
| 2019 FY | 1.5 Million EUR | -75.99% |
| 2019 Q4 | 2.43 Million EUR | 262.29% |
| 2019 Q3 | -1.5 Million EUR | 81.12% |
| 2019 Q1 | 6.2 Million EUR | 16.11% |
| 2018 Q2 | -928 Thousand EUR | -128.98% |
| 2018 Q1 | 3.2 Million EUR | 177.23% |
| 2018 FY | 6.26 Million EUR | 258.35% |
| 2018 Q4 | 5.34 Million EUR | 494.03% |
| 2018 Q3 | -1.35 Million EUR | -46.12% |
| 2017 Q2 | 1.34 Million EUR | 181.72% |
| 2017 Q4 | -4.14 Million EUR | -155.3% |
| 2017 Q3 | -1.62 Million EUR | -221.1% |
| 2017 FY | -3.95 Million EUR | 90.71% |
| 2017 Q1 | 476 Thousand EUR | 113.64% |
| 2016 Q4 | -3.49 Million EUR | 13.22% |
| 2016 FY | -42.56 Million EUR | -113.54% |
| 2016 Q3 | -4.02 Million EUR | 87.56% |
| 2016 Q2 | -32.33 Million EUR | -1088.31% |
| 2016 Q1 | -2.72 Million EUR | -3.62% |
| 2015 Q2 | -8.69 Million EUR | -45.81% |
| 2015 Q1 | -5.96 Million EUR | 39.48% |
| 2015 FY | -19.93 Million EUR | 16.3% |
| 2015 Q4 | -2.62 Million EUR | 1.06% |
| 2015 Q3 | -2.65 Million EUR | 69.47% |
| 2014 Q3 | -2.99 Million EUR | 33.71% |
| 2014 FY | -23.81 Million EUR | -14.2% |
| 2014 Q1 | -6.44 Million EUR | -82.28% |
| 2014 Q2 | -4.52 Million EUR | 29.9% |
| 2014 Q4 | -9.85 Million EUR | -228.7% |
| 2013 Q3 | -9.6 Million EUR | -91.3% |
| 2013 Q4 | -3.53 Million EUR | 63.17% |
| 2013 FY | -20.85 Million EUR | -62.52% |
| 2013 Q1 | -2.42 Million EUR | 32.2% |
| 2013 Q2 | -5.02 Million EUR | -107.18% |
| 2012 Q3 | -2.41 Million EUR | 0.0% |
| 2012 Q4 | -3.57 Million EUR | -48.28% |
| 2012 FY | -12.83 Million EUR | -188.32% |
| 2011 FY | -4.45 Million EUR | 47.12% |
| 2010 FY | -8.41 Million EUR | -33.71% |
| 2009 FY | -6.29 Million EUR | -99.59% |
| 2008 FY | -3.15 Million EUR | 34.09% |
| 2007 FY | -4.78 Million EUR | -2065.16% |
| 2006 FY | -221 Thousand EUR | 84.55% |
| 2005 FY | -1.43 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Boiron SA | 42.29 Million EUR | 294.105% |
| Laboratorios Farmaceuticos Rovi, S.A. | 220.25 Million EUR | 137.269% |
| Vetoquinol SA | 74.26 Million EUR | 210.534% |
| AB Science S.A. | -13.42 Million EUR | -511.267% |
| Nanobiotix S.A. | -26.77 Million EUR | -206.535% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | -246.944% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | -184.659% |
| BioSenic S.A. | -7.04 Million EUR | -1066.009% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 35.555% |
| Formycon AG | -369 Thousand EUR | -22145.799% |